OPUS GENETICS INC (IRD)
Health Care · biotechnology / gene therapy · NASDAQ
Opus Genetics is a clinical-stage gene therapy company developing a portfolio of durable, one-time treatments for rare inherited retinal diseases.
What OPUS GENETICS INC does
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing one-time, durable adeno-associated virus (AAV)-based gene therapies for inherited retinal diseases (IRDs). Its lead program is OPGx-LCA5 for LCA5-related mutations, alongside a portfolio targeting genes such as BEST1, RHO, CNGB1, RDH12, MERTK, and NMNAT1. The company also maintains a small-molecule ophthalmic program, including an FDA-approved phentolamine ophthalmic solution.
Recent developments
The company expects top-line data for OPGx-BEST1 Cohort 1 in September 2026 and plans to begin dosing in its OPGx-LCA5 Phase 3 registrational trial in Q4 2026. Management has guided that cash resources are sufficient to fund operations into 2029.
From OPUS GENETICS INC's filing of 2026-08-06.
Themes: gene therapy, rare diseases / orphan drugs, ophthalmology, inherited retinal diseases
Fundamentals
- Price$4.46 as of 2026-10-08 close
- Market cap$371M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+117.6% 2025-10-08 close $2.05 → 2026-10-08 close $4.46
- P/En/a negative earnings
- Net margin-349.3% FY2025, SEC XBRL
- ROE-323.1% FY2025, SEC XBRL
- Debt / equity0.07 as of 2026-09-02
- Revenue growth (YoY)-12.2% as of 2026-09-02
- Revenue CAGR (3y)-29.1% SEC XBRL
- Beta0.78 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How IRD compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OPUS GENETICS INC looks technically
OPUS GENETICS INC (IRD) is trading 13.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 283 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 21 trading days ago. It is 36.9% below its highest point of the past year. Trading volume is unusually light — only about 33% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 13.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +13.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.42 | $4.42 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.94 | $3.94 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 4.41. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 283 trading days ago — a "golden cross", a bullish long-term signal | 283 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 27.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($4.19 to $5.55) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 19.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.07 | $7.07 |
|---|---|---|
| From the 52-week high | it is 36.9% below its 52-week high (its highest price of the past year) | -36.9% |
| Above the 52-week low | it is 197.3% above its 52-week low (its lowest price of the past year) | +197.3% |
| Below the 52-week high | it is 36.9% below its highest point of the past year | 36.9% |
| Since a 20-day breakout | it made a new 20-day high about 21 trading days ago | 21 sessions |
| Since a 55-day breakout | it made a new 55-day high about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $4795.20 (set on 2008-05-27) | $4795.20 |
| Given back of the 52-week move | over the past year its closes ranged ($1.64 to $6.07), and it has given back roughly a third of its rise from last year’s low — 36% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.19 to $3.33. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 36.3% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 1.4% above a support level at $4.40 — a price it turned at twice since 2026-07-06, most recently on 2026-08-25. Since 2024-10-08 it has 7 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $0.65 (set on 2025-04-10) | $0.65 |
| Above the all-time low | it is 586.2% above its all-time low | +586.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 70th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.394 between its high and its low — about 8.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.394 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.00 and $6.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.00 – $5.01 – $6.01 |
| Typical daily range (% of price) | its price moves about 8.8% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.8% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges above its 200-day average price (13.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 33% of its 30-day average | 0.33× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
4
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.83% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.7 percentage points (the stock gained 2.8% while the market gained 1.0%) | +1.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 5.0 percentage points (the stock gained 8.8% while the market gained 3.8%) | +5.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.7 percentage points (the stock lost 3.3% while the market gained 17.5%) | -20.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 102.6 percentage points (the stock gained 117.6% while the market gained 15.0%) | +102.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.2% of the share price. | +14.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.62 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | -3.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.20 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -14.2% |
Price levels it has turned at before
IRD last closed at $4.46 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.40 | Support | 1.4% below the last close | turned there twice · 2026-07-06 to 2026-08-25 |
| $4.27 | Support | 4.3% below the last close | turned there twice · 2026-03-30 to 2026-06-23 |
| $5.31 | Resistance | 19.1% above the last close | turned there twice · 2026-03-10 to 2026-09-30 |
| $3.53 | Support | 20.8% below the last close | turned there three times · 2026-08-07 to 2026-08-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $4.41.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $5.29 and $6.23 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $7.07.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · lagging the market · Printed a hammer candle after a decline · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 17 analysts
- Mean price target$13.41 range $8.00 – $20.00; median $13.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IRD
- Consensus EPS estimate-$0.1525 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.00036 from -$0.1529, on 2026-09-04, 35-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High clinical development and regulatory risk associated with novel gene therapy technology.","Dependence on a pipeline of early-to-mid-stage clinical candidates and the need for significant future capital.","Potential for intense competition and difficulties in securing third-party reimbursement for novel orphan disease treatments."]
What changed in the latest 10-Q
AI-assisted comparison of IRD's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Added risk bullet: 'Instability and operational disruptions at government agencies, such as the FDA, may adversely impact our development and commercialization plans by causing delays and requiring the use of additional, unforeseen resources to obtain regulatory approval for trials or products in our pipeline' (filed 2026-05-12)
- Added expanded language to regulatory environment risk: 'including due to government shutdowns and disruptions at government agencies, which cause delays, requires the use of additional, unforeseen resources, affects our pipeline stability' (filed 2026-05-12)
- Removed:
- Removed three risk bullets specific to post-Opus Acquisition integration and strategy: clinical data on IRDs from small patient groups, failure to integrate Opus Acquisition, and acquisition impact on business value (filed 2025-11-12)
- Removed risk bullet: 'Our current focus on the cash-pay utilization for future sales of RYZUMVI may limit our ability to increase sales or achieve profitability with this product' (filed 2025-11-12)
- Removed reference to 'Viatris License Agreement (as defined below)' from licensing arrangements risk (filed 2025-11-12)
- Removed specific reference to 'Nasdaq Capital Market ("Nasdaq")' in delisting risk (filed 2025-11-12)
- Removed language 'delisting could adversely affect our ability to access capital markets' from delisting risk (filed 2025-11-12)
- Reworded:
- Changed 'for the year ended December 31, 2024' to 'for the year ended December 31, 2025' in opening paragraph reference to Form 10-K (filed 2026-05-12)
- Changed 'drug research and discovery resources' to 'drug research and discovery capabilities' (filed 2026-05-12)
- Changed 'financial services markets' to 'financial markets' in capital access risk (filed 2026-05-12)
- Changed 'which affects our pipeline stability and could impair our ability to compete' to 'including due to government shutdowns and disruptions at government agencies, which cause delays, requires the use of additional, unforeseen resources, affects our pipeline stability, and could impair our ability to compete' in regulatory environment risk (filed 2026-05-12)
- Changed 'The market price of our common stock is expected to be volatile' to 'The market price of our common stock is expected to be volatile and if we fail to comply with the continued listing standards of Nasdaq, our common stock may be delisted' (filed 2026-05-12)
- Notes:
- The older filing text appears truncated at the end (cuts off mid-word on 'expe'), so the full extent of removals in that section cannot be fully assessed
- This comparison covers the Forward-Looking Statements subsection of the MD&A; other MD&A content beyond this section was not provided for comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($3M) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 6 sells ($3M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 13 sells ($11M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-30. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IRD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding IRD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 5,238,089
- Reported value $21,528,547
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IRD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IRD had 12,578,772 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IRD had 15.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.51 days to cover at the same settlement.
- Reported short interest (shares) 12,578,772
- Short interest (% of shares outstanding) 15.1%
- Prior settlement (shares) 10,912,085
- Reported change 15.27%
- Days to cover (reported) 1.51
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Spark Therapeutics (Roche)
- REGENXBIO (RGNX)
- Editas Medicine (EDIT)
- Iveric Bio (Astellas)
- Krystal Biotech (KRYS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IRD vs…
OPUS GENETICS INC is found in…
Frequently asked questions
What does OPUS GENETICS INC (IRD) do?
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing one-time, durable adeno-associated virus (AAV)-based gene therapies for inherited retinal diseases (IRDs). Its lead program is OPGx-LCA5 for LCA5-related mutations, alongside a portfolio targeting genes such as BEST1, RHO, CNGB1, RDH12, MERTK, and NMNAT1. The company also maintains a small-molecule ophthalmic program, including an FDA-approved phentolamine ophthalmic solution.
What sector is OPUS GENETICS INC (IRD) in?
OPUS GENETICS INC (IRD) is classified in the Health Care sector. Its industry is biotechnology / gene therapy. It trades on NASDAQ.
Who are OPUS GENETICS INC's (IRD) competitors?
Notable peers of OPUS GENETICS INC (IRD) include Spark Therapeutics (Roche), REGENXBIO, Editas Medicine, Iveric Bio (Astellas) and Krystal Biotech. This peer set is informational only — not financial advice.
Is OPUS GENETICS INC (IRD) overbought or oversold right now?
OPUS GENETICS INC (IRD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IRD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.